Korro Bio Shares Decline Following Disappointing Results in Initial KRRO-110 Trial
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 13 2025
0mins
Should l Buy KRRO?
Source: SeekingAlpha
Clinical Trial Results: Korro Bio's KRRO-110 failed to meet expected functional protein levels in its early-stage trial for alpha-1 antitrypsin deficiency, leading to a 78% drop in stock price.
Analyst Reactions: RBC Capital Markets downgraded Korro Bio's stock to a Sector Perform rating with Speculative Risk and significantly reduced their price target from $85 to $8.
Financial Position: As of Q3 2025, Korro Bio reported $102.5 million in cash and marketable securities, planning to extend its financial runway into late 2027 through strategic restructuring.
Market Sentiment: Despite the disappointing trial results, analysts maintain a belief in the potential of Korro Bio's broader platform.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy KRRO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on KRRO
Wall Street analysts forecast KRRO stock price to rise
8 Analyst Rating
0 Buy
8 Hold
0 Sell
Hold
Current: 12.300
Low
7.00
Averages
25.75
High
81.00
Current: 12.300
Low
7.00
Averages
25.75
High
81.00
About KRRO
Korro Bio, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops, and commercializes genetic medicines based on editing ribonucleic acid (RNA), enabling treatment of both rare and highly prevalent diseases. The Company is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, it is expanding the reach of genetic medicines. Using its oligonucleotide-based approach, the Company brings its medicines to patients by leveraging its proprietary platform. The Company’s first development candidate, KRRO-110, is in development as a potential treatment for Alpha-1 Antitrypsin Deficiency (AATD) that has the potential to be disease-modifying and provide a differentiated therapeutic option.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Korro Bio Secures $85 Million PIPE Financing to Advance RNA Editing Programs
- Financing Amount: Korro Bio has secured approximately $85 million through PIPE financing, which will support the reporting of clinical data for multiple RNA editing programs, particularly the KRRO-121 project for patients with urea cycle disorders, indicating the company's strong growth potential in gene therapy.
- Investor Participation: The financing was led by Venrock Healthcare Capital Partners and attracted participation from several new and existing investors, including ADAR1 Capital Management and New Enterprise Associates, reflecting market confidence and support for Korro's RNA editing technology.
- Cash Flow Extension: Following this financing, Korro expects to extend its cash runway into the second half of 2028, ensuring operational stability for several years alongside $85.2 million in cash and cash equivalents as of December 31, 2025.
- Clinical Development Milestones: The funds will drive clinical development for KRRO-121 and the GalNAc-conjugated oligonucleotide program targeting alpha-1 antitrypsin deficiency, further solidifying Korro's market position and technological advantages in the gene therapy sector.
See More
Korro Bio Secures $85 Million in PIPE Financing
- Financing Agreement: Korro Bio has entered into a subscription agreement for a private investment in public equity, securing approximately $85 million, which reflects strong market confidence in its future growth prospects.
- Stock Issuance Details: Under the agreement, Korro is selling 4.5 million shares of common stock at $11.11 per share and offering 3.15 million pre-funded warrants at an exercise price of $0.001, thereby enhancing its capital structure.
- Use of Funds: The net proceeds from this financing, combined with $85.2 million in cash and cash equivalents as of December 31, 2025, will extend the company's cash runway into the second half of 2028 and support the clinical development of its pipeline for genetic disease therapies.
- Advancing Clinical Milestones: The funding will facilitate clinical development milestones for key pipeline assets, including clinical data for KRRO-121 and the GalNAc-conjugated alpha-1 antitrypsin deficiency program, ensuring ongoing innovation in treatment areas.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, although specific upgrades and downgrades are not disclosed, this shift could influence investor decisions and market sentiment.
- Market Reaction Expectations: Changes in analyst ratings typically trigger market volatility, prompting investors to monitor these shifts to assess potential investment opportunities and risks, especially in the current economic climate.
- Investor Focus: For those considering buying CHWY stock, analysts' opinions will serve as a crucial reference point, potentially impacting their buying decisions and the stock's market performance.
- Rating Change Transparency: While the article does not provide specific details on rating changes, it emphasizes the importance of the analyst ratings page, where investors can access comprehensive information on rating changes to make informed investment choices.
See More
Korro Bio's KRRO-121 Receives Strong Analyst Upgrades
- Analyst Upgrades: H.C. Wainwright upgraded Korro Bio to ‘Buy’ from ‘Neutral’ with a $20 price target, asserting that KRRO-121 serves as an independently risk-mitigated asset, thereby enhancing market confidence in the stock.
- Stock Price Surge: Shares of Korro Bio jumped 13% on Thursday following optimistic upgrades from multiple analysts, indicating strong market confidence in the new drug development candidate KRRO-121, which is likely to attract more investor interest.
- Clinical Trial Plans: Korro intends to file for clinical trials of KRRO-121 in the second half of 2026, targeting hyperammonemia treatment, which could present new growth opportunities for the company in addressing this critical metabolic condition.
- Market Sentiment Shift: Retail sentiment on Stocktwits for KRRO stock shifted from ‘bearish’ to ‘extremely bullish’ in the past 24 hours, with message volume increasing from ‘high’ to ‘extremely high’, reflecting strong optimism among investors regarding the company’s prospects.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Updates: Top Wall Street analysts have adjusted their ratings on several companies, reflecting a shift in market sentiment that could influence investor decisions and market trends.
- Overview of Changes: The rating changes include upgrades, downgrades, and new initiations, providing investors with a comprehensive view of market analysis to better seize investment opportunities.
- Investor Attention: The changes in analyst ratings may draw investor interest towards FTNT stock, particularly in the current market environment where investors need to closely monitor these shifts for informed decision-making.
- Market Impact Assessment: Analyst rating adjustments not only affect the performance of individual stocks but can also influence overall market sentiment, prompting investors to consider these factors to optimize their investment portfolios.
See More
Wall Street Analysts Adjust META Stock Outlook
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on META stock, reflecting varying market perspectives on the company's future performance, which could influence investor decisions.
- Increased Market Attention: As analysts focus more on META, investors may reassess their portfolios, particularly against the backdrop of volatility in tech stocks.
- Rating Page Update: Comprehensive information on analyst rating changes can be found on our analyst ratings page, offering a complete view of META and other stocks to aid investors in making informed decisions.
- Lack of Investment Advice: While rating changes are provided, Benzinga does not offer specific investment advice, leaving investors to evaluate risks and rewards independently.
See More
Korro Bio Secures $85 Million PIPE Financing to Advance RNA Editing Programs
- Financing Amount: Korro Bio has secured approximately $85 million through PIPE financing, which will support the reporting of clinical data for multiple RNA editing programs, particularly the KRRO-121 project for patients with urea cycle disorders, indicating the company's strong growth potential in gene therapy.
- Investor Participation: The financing was led by Venrock Healthcare Capital Partners and attracted participation from several new and existing investors, including ADAR1 Capital Management and New Enterprise Associates, reflecting market confidence and support for Korro's RNA editing technology.
- Cash Flow Extension: Following this financing, Korro expects to extend its cash runway into the second half of 2028, ensuring operational stability for several years alongside $85.2 million in cash and cash equivalents as of December 31, 2025.
- Clinical Development Milestones: The funds will drive clinical development for KRRO-121 and the GalNAc-conjugated oligonucleotide program targeting alpha-1 antitrypsin deficiency, further solidifying Korro's market position and technological advantages in the gene therapy sector.
See More
Korro Bio Secures $85 Million in PIPE Financing
- Financing Agreement: Korro Bio has entered into a subscription agreement for a private investment in public equity, securing approximately $85 million, which reflects strong market confidence in its future growth prospects.
- Stock Issuance Details: Under the agreement, Korro is selling 4.5 million shares of common stock at $11.11 per share and offering 3.15 million pre-funded warrants at an exercise price of $0.001, thereby enhancing its capital structure.
- Use of Funds: The net proceeds from this financing, combined with $85.2 million in cash and cash equivalents as of December 31, 2025, will extend the company's cash runway into the second half of 2028 and support the clinical development of its pipeline for genetic disease therapies.
- Advancing Clinical Milestones: The funding will facilitate clinical development milestones for key pipeline assets, including clinical data for KRRO-121 and the GalNAc-conjugated alpha-1 antitrypsin deficiency program, ensuring ongoing innovation in treatment areas.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, although specific upgrades and downgrades are not disclosed, this shift could influence investor decisions and market sentiment.
- Market Reaction Expectations: Changes in analyst ratings typically trigger market volatility, prompting investors to monitor these shifts to assess potential investment opportunities and risks, especially in the current economic climate.
- Investor Focus: For those considering buying CHWY stock, analysts' opinions will serve as a crucial reference point, potentially impacting their buying decisions and the stock's market performance.
- Rating Change Transparency: While the article does not provide specific details on rating changes, it emphasizes the importance of the analyst ratings page, where investors can access comprehensive information on rating changes to make informed investment choices.
See More
Korro Bio's KRRO-121 Receives Strong Analyst Upgrades
- Analyst Upgrades: H.C. Wainwright upgraded Korro Bio to ‘Buy’ from ‘Neutral’ with a $20 price target, asserting that KRRO-121 serves as an independently risk-mitigated asset, thereby enhancing market confidence in the stock.
- Stock Price Surge: Shares of Korro Bio jumped 13% on Thursday following optimistic upgrades from multiple analysts, indicating strong market confidence in the new drug development candidate KRRO-121, which is likely to attract more investor interest.
- Clinical Trial Plans: Korro intends to file for clinical trials of KRRO-121 in the second half of 2026, targeting hyperammonemia treatment, which could present new growth opportunities for the company in addressing this critical metabolic condition.
- Market Sentiment Shift: Retail sentiment on Stocktwits for KRRO stock shifted from ‘bearish’ to ‘extremely bullish’ in the past 24 hours, with message volume increasing from ‘high’ to ‘extremely high’, reflecting strong optimism among investors regarding the company’s prospects.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Updates: Top Wall Street analysts have adjusted their ratings on several companies, reflecting a shift in market sentiment that could influence investor decisions and market trends.
- Overview of Changes: The rating changes include upgrades, downgrades, and new initiations, providing investors with a comprehensive view of market analysis to better seize investment opportunities.
- Investor Attention: The changes in analyst ratings may draw investor interest towards FTNT stock, particularly in the current market environment where investors need to closely monitor these shifts for informed decision-making.
- Market Impact Assessment: Analyst rating adjustments not only affect the performance of individual stocks but can also influence overall market sentiment, prompting investors to consider these factors to optimize their investment portfolios.
See More
Wall Street Analysts Adjust META Stock Outlook
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on META stock, reflecting varying market perspectives on the company's future performance, which could influence investor decisions.
- Increased Market Attention: As analysts focus more on META, investors may reassess their portfolios, particularly against the backdrop of volatility in tech stocks.
- Rating Page Update: Comprehensive information on analyst rating changes can be found on our analyst ratings page, offering a complete view of META and other stocks to aid investors in making informed decisions.
- Lack of Investment Advice: While rating changes are provided, Benzinga does not offer specific investment advice, leaving investors to evaluate risks and rewards independently.
See More
